Copyright: The Authors.
Licence: This open access article is licenced under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Debinski W, editor. Gliomas [Internet]. Brisbane (AU): Exon Publications; 2021 Apr 30. doi: 10.36255/exonpublications.gliomas.2021.chapter10
Figure 2
Schematic representation of the protocol for collecting and analyzing the molecular profile of glioma samples. After collection and adequate conditioning of the tumor sample, IHC and FISH techniques will be performed to determine the expression of the markers: IDH 1 and 2; ATRX and 1p/19q codeletion, respectively. qPCR analyzes will be carried out to evaluate the molecular markers modules: p53 (TP53), RB (CDKN2A), PI3K (PIK3CA), and RTK (EGFR and NF1). Other related molecular markers also will be evaluated such as MGMT and PDGFRA, AKT, mTOR, Rhoa, and ROCK (related to tumor development and also with cell migration and proliferation pathways, respectively). The establishment of the culture sample will analyze other parameters and also will be used, together with tissue samples, for the creation of a biobank.
- Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.[Acta Neuropathol Commun. 2017]Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, et al. Acta Neuropathol Commun. 2017 May 22; 5(1):39. Epub 2017 May 22.
- Review Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.[Curr Treat Options Oncol. 2016]Review Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Chen R, Cohen AL, Colman H. Curr Treat Options Oncol. 2016 Aug; 17(8):42.
- Review Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine.[Am Soc Clin Oncol Educ Book. 2...]Review Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine.Chang SM, Cahill DP, Aldape KD, Mehta MP. Am Soc Clin Oncol Educ Book. 2016; 35:75-81.
- Review Individualized targeted therapy for glioblastoma: fact or fiction?[Cancer J. 2012]Review Individualized targeted therapy for glioblastoma: fact or fiction?Weller M, Stupp R, Hegi M, Wick W. Cancer J. 2012 Jan-Feb; 18(1):40-4.
- PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.[Acta Neuropathol Commun. 2015]PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.Draaisma K, Wijnenga MM, Weenink B, Gao Y, Smid M, Robe P, van den Bent MJ, French PJ. Acta Neuropathol Commun. 2015 Dec 23; 3:88. Epub 2015 Dec 23.
- Figure 2, [Schematic representation of the protocol...]. - GliomasFigure 2, [Schematic representation of the protocol...]. - Gliomas
Your browsing activity is empty.
Activity recording is turned off.
See more...